The effects of the study drugs will be evaluated in the following predefined subgroups of patients:

		Age (above/below the median value)
		Left ventricular function (EF% >40% vs =<40%)
		Etiology (ischemic vs non-ischemic)
		Functional capacity (NYHA class II vs III-IV)
		Diabetes (yes vs no)
		Baseline total cholesterol levels (above/below the median value)

Patients with preserved LV function (EF >40%) will be further stratified in 2 subgroups with and without probable diastolic heart failure according to the criteria by Vasan.

The end-point for all the subgroup analyses is the combined outcome measure of all-cause mortality or hospital admission for cardiovascular reasons.